ArticlemBio2026
Dynamics of B-cell response in MERS-CoV patients and survivors with hybrid immunity.
Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) causes a highly lethal respiratory infection for which no vaccines or antiviral therapeutics are currently available. Understanding the immune response is critical for designing effective therapeutics. Here, we comprehensively characterized the dynamics of B-cell responses in severely infected MERS-CoV patients and survivors with SARS-CoV-2 exposure history. Infected patients developed robust neutralizing antibody responses within 1 month of illness, with moderate-to-high cross-neutralization activity against SARS-CoV-2. The enhanced neutralization activity coincided with an increased abundance of specific mutated, class-switched IgG clones. Notably, one such clone was detected at moderate prevalence in both patients, and its expansion was accompanied by high neutralization activity against both viruses. Conversely, MERS-CoV survivors demonstrated higher neutralization activity against MERS-CoV after vaccination, despite minimal changes in antibody titers and limited alterations in B-cell repertoire properties. This suggests that the enhanced neutralization activity may be mediated by the reactivation and expansion of cross-reactive memory B cells targeting conserved epitopes, originally generated in response to the virus that triggered the primary immune response. These findings provide valuable insights into the B-cell repertoire landscape during natural MERS-CoV infection and highlight the potential for identifying broadly neutralizing antibodies in individuals with hybrid immunity.IMPORTANCEThis study examines the immune responses of MERS-CoV patients and survivors who have had confirmed exposure to SARS-CoV-2. It offers a unique opportunity to characterize cross-reactive B-cell responses in individuals possessing hybrid immunity to both pathogenic coronaviruses. To our knowledge, no previous studies have examined longitudinal changes in the B-cell repertoire in MERS-CoV patients or survivors before and after SARS-CoV-2 vaccination. Our findings reveal enhanced neutralization activity against both MERS-CoV and SARS-CoV-2 following infection or vaccination, which appears to be associated with distinct patterns of B-cell repertoire dynamics. Notably, the data strongly suggest the presence of potent cross-neutralizing antibody responses, particularly in MERS-CoV patients, driven by dominant B-cell clones. These results underscore the potential for identifying broadly neutralizing antibodies in individuals with hybrid immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.